Lucila Garcia-Contreras, Ph.D.
Phone (405) 271-6593 x47205
Fax (405) 271-7505
Office CPB 321
The research goal of my laboratory is “Targeted Drug Delivery” and involves the rational design of dosage forms and their in vitro evaluation, which are used to design in vivo studies. In turn, the information obtained in in vitro and in vivo studies is used to understand the underlying reasons of the performance of the dosage form with the objective of improving its formulation design to achieve the desired therapeutic effect.
A recent project that illustrates this process is the formulation of a novel molecule with anticancer and antimicrobial activity for pulmonary delivery as nanocrystals or microparticles. In vitro evaluation included size analysis using Scanning Electron Microscopy (SEM) and laser diffraction; stability, using (Fourier-transform infrared spectroscopy (FTIR), X-ray diffraction (XRD) and differential scanning calorimetry (DSC). We determined the aerosol performance of these formulations using commercial dry powder inhalers and performed pharmacokinetic studies to determine the disposition of the drug after pulmonary administration to mice. Lastly, in collaboration with Dr. Jie Wu from the OUHSC Department of Pathology, we assessed the efficacy of the nanocrystals in a transgenic mouse model of adenocarcinoma.
My laboratory also designs dosage forms for oral, vaginal and transdermal administration following same procedure. A second line of investigation of my laboratory is the development of needle-less vaccines to provide mucosal and systemic immunization. We are interested in elucidating the role of cell mediated immune (CMI) response and humoral immunity to the overall protection provided by the vaccine. Examples of vaccines studied in my laboratory include vaccines against tuberculosis, West Nile Virus, Diphtheria and Shigellosis.
Publications & Presentations
- 166. Abu-Izza K A, Garcia-Contreras L, Lu D R. Preparation and evaluation of sustained release AZT-loaded microspheres: optimization of the release characteristics using response surface methodology. Journal of pharmaceutical sciences. 1996; 85 : 144-9
167. Garcia-Contreras L, Lu D R. Preparation and characterization of biodegradable cisplatin microspheres for brain implantation. American Association of Pharmaceutical Scientists. 1995
168. Abu-Izza K, Garcia-Contreras L, Lu D R. Preparation and optimization of a sustained release microsphere formulation of zidovudine (AZT. American Association of Pharmaceutical Scientists. 1994
- 1. Neuropeptide modulation of cerebral blood flow to improve neurological and psychological outcomes following TBI in the presence. DOD. Start Date: 2023. End Date: 2027.
2. Novel Ophthalmic Product for Corneal Infections and Injuries. NIH. Start Date: 2021. End Date: 2023.
3. Drug Targeting Oxysterol-Binding Protein (OSBP) for Antiviral Treatment of SARS-CoV-2 Infections. Intramural Funding. Start Date: 2022. End Date: 2023.
4. Understanding the effects of sphero-cylinder drug particle shape to enhance small-airway drug delivery for better emphysema treatment outcomes. Misc Non-Federal. Start Date: 2019. End Date: 2022.
5. Targeting HPV Consequences in a Cervical Cancer Clinical Trial. NIH. Start Date: 2016. End Date: 2022.
Awards and Honors
- 1. University of Oklahoma Health Sciences Center. Carlisle and Lurline Mabrey Presidential Professorship. Date: 2020.
2. Respiratory Drug Delivery. Posters on the podium. Date: 2012.
3. Graduate Research Association of Students in Pharmaceutics Best poster presentation. Date: 1997.
4. Fulbright. Fulbright-Conacyt Scholarship. Date: 1993.
5. National Autonomous University of Mexico. Gabino Barreda Medal-UNAM. Date: 1991.
- 1. Degree: Post doctoral education. the University of North Carolina at Chapel Hill. Date: 2001.
2. Degree: Ph D. The University of Georgia. Date: 1999.
3. Degree: MS. The University of Georgia. Date: 1995.
4. Degree: Chemist Pharmacist Biologist. National Autonomous University of Mexico. Date: 1991.